We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SEI Investments (SEIC) Rolls Out Share-Buyback Plan Worth $250M
Read MoreHide Full Article
SEI Investments (SEIC - Free Report) continues to reward its shareholders through dividend hikes or additional share repurchases. The company recently announced its latest share-buyback plan, with authorization to repurchase common shares worth $250 million.
Notably, the latest authorization increases the existing program to about $272 million. Since the beginning of 2020, the company has bought back about 1.677 million shares for $96 million.
SEI Investments has also been paying quarterly dividends, along with regular hikes. Since 2011, the company has raised its dividend nine times. Its semi-annual dividend was last hiked in December 2019 by 6.1% to 35 cents per share.
"Today, the world is coping with a pandemic, posing challenges for companies and our way of life. Protecting the health and well-being of our employees, their families, and clients is our priority," said Alfred P. West, Jr., SEI chairman and CEO. "We believe we are well-prepared to manage through this period of disruption and uncertainty. While the SEI team is currently in a work-from-home environment for all but essential operations personnel, our operational integrity remains strong globally. Our innovative workforce, strong cash flow and resilient operations will help us navigate these turbulent times and continue to deliver for our clients," noted the CEO.
With strong liquidity and balance-sheet position, we believe SEI Investments will continue to reward its shareholders, in the days to come. Let’s dig deeper into its financials and fundamental strengths, and see if the company is worth considering.
Earnings per Share (EPS) Growth: The company’s earnings improved at a rate of 13.9% over the last three to five years, higher than the industry’s growth rate of 5.6%. Moreover, its earnings are projected to be up 8.3% in 2020 and 11% in 2021.
Further, the company’s long-term (three-five years) projected EPS growth rate of 12% promises reward for investors.
Revenue Strength: Aided by continued growth in assets, SEI Investments’ revenues witnessed a CAGR of 5.4% over the last six years (2014-2019). Notably, its total AUM witnessed a CAGR of 7.5% over the last four years (2016-2019).
Supported by the company’s diversified product mix, solid global presence and strong assets balance, its revenues are expected to rise further. In fact, its projected sales growth rate of 4.4% for 2020 and 5.4% for 2021 ensure continuation of the upward trend in revenues.
Strong Leverage: SEI Investments currently has a debt/equity ratio of 0.02, lower than the industry’s debt/equity ratio of 0.20. This suggests that the company will likely perform better than its peers in a dynamic business environment.
Superior Return on Equity (ROE): SEI Investments’ ROE supports its growth potential. Its current ROE of 29.88% compares favorably with the industry’s average of 13.31%. This highlights its efficiency in using shareholder funds.
Similar Moves
During the current quarter, among other finance stocks, Popular, Inc. (BPOP - Free Report) , Stifel Financial Corp. (SF - Free Report) and Jefferies Financial Group Inc. (JEF - Free Report) have also announced share-repurchase authorizations.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
SEI Investments (SEIC) Rolls Out Share-Buyback Plan Worth $250M
SEI Investments (SEIC - Free Report) continues to reward its shareholders through dividend hikes or additional share repurchases. The company recently announced its latest share-buyback plan, with authorization to repurchase common shares worth $250 million.
Notably, the latest authorization increases the existing program to about $272 million. Since the beginning of 2020, the company has bought back about 1.677 million shares for $96 million.
SEI Investments has also been paying quarterly dividends, along with regular hikes. Since 2011, the company has raised its dividend nine times. Its semi-annual dividend was last hiked in December 2019 by 6.1% to 35 cents per share.
"Today, the world is coping with a pandemic, posing challenges for companies and our way of life. Protecting the health and well-being of our employees, their families, and clients is our priority," said Alfred P. West, Jr., SEI chairman and CEO. "We believe we are well-prepared to manage through this period of disruption and uncertainty. While the SEI team is currently in a work-from-home environment for all but essential operations personnel, our operational integrity remains strong globally. Our innovative workforce, strong cash flow and resilient operations will help us navigate these turbulent times and continue to deliver for our clients," noted the CEO.
SEI Investments has depreciated 28.1% in the last six months compared with the industry’s decline of 24.6%. Currently, the stock carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
With strong liquidity and balance-sheet position, we believe SEI Investments will continue to reward its shareholders, in the days to come. Let’s dig deeper into its financials and fundamental strengths, and see if the company is worth considering.
Earnings per Share (EPS) Growth: The company’s earnings improved at a rate of 13.9% over the last three to five years, higher than the industry’s growth rate of 5.6%. Moreover, its earnings are projected to be up 8.3% in 2020 and 11% in 2021.
Further, the company’s long-term (three-five years) projected EPS growth rate of 12% promises reward for investors.
Revenue Strength: Aided by continued growth in assets, SEI Investments’ revenues witnessed a CAGR of 5.4% over the last six years (2014-2019). Notably, its total AUM witnessed a CAGR of 7.5% over the last four years (2016-2019).
Supported by the company’s diversified product mix, solid global presence and strong assets balance, its revenues are expected to rise further. In fact, its projected sales growth rate of 4.4% for 2020 and 5.4% for 2021 ensure continuation of the upward trend in revenues.
Strong Leverage: SEI Investments currently has a debt/equity ratio of 0.02, lower than the industry’s debt/equity ratio of 0.20. This suggests that the company will likely perform better than its peers in a dynamic business environment.
Superior Return on Equity (ROE): SEI Investments’ ROE supports its growth potential. Its current ROE of 29.88% compares favorably with the industry’s average of 13.31%. This highlights its efficiency in using shareholder funds.
Similar Moves
During the current quarter, among other finance stocks, Popular, Inc. (BPOP - Free Report) , Stifel Financial Corp. (SF - Free Report) and Jefferies Financial Group Inc. (JEF - Free Report) have also announced share-repurchase authorizations.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>